N-((3,5-dimethyl-1H-pyrazol-4-yl)carbamoyl)-2-((3-methylquinoxalin-2-yl)thio)acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-((3,5-dimethyl-1H-pyrazol-4-yl)carbamoyl)-2-((3-methylquinoxalin-2-yl)thio)acetamide
• 英文别名: 1-(3,5-dimethyl-1H-pyrazol-4-yl)-3-[2-(3-methylquinoxalin-2-ylsulfanyl)acetyl]urea；N-[(3,5-dimethyl-1H-pyrazol-4-yl)carbamoyl]-2-(3-methylquinoxalin-2-yl)sulfanylacetamide
• 化学式: C₁₇H₁₈N₆O₂S
• 分子量: 370.435
• InChiKey: AXMGTACDPLMOAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  138
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3,5-二甲基-1H-吡唑-4-胺 在 sodium acetate 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 N-((3,5-dimethyl-1H-pyrazol-4-yl)carbamoyl)-2-((3-methylquinoxalin-2-yl)thio)acetamide
  参考文献：
  名称：

  Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress

  摘要：

  We prepared a series of quinoxalin-2-mercapto-acetyl-urea analogs and evaluated them for their ability to inhibit viral egress in our Marburg and Ebola VP40 VLP budding assays in HEK293T cells. We also evaluated selected compounds in our bimolecular complementation assay (BiMC) to detect and visualize a Marburg mVP40-Nedd4 interaction in live mammalian cells. Antiviral activity was assessed for selected compounds using a live recombinant vesicular stomatitis virus (VSV) (M40 virus) that expresses the EBOV VP40 PPxY L-domain. Finally selected compounds were evaluated in several ADME assays to have an early assessment of their drug properties. Our compounds had low nM potency in these assays (e.g., compounds 21, 24, 26, 39), and had good human liver microsome stability, as well as little or no inhibition of P450 3A4. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.06.053

文献信息

• [EN] NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME<br/>[FR] NOUVEAUX COMPOSÉS ANTIVIRAUX ET LEURS MÉTHODES D'UTILISATION
  申请人：UNIV PENNSYLVANIA

  公开号：WO2015153554A1

  公开（公告）日：2015-10-08

  The present invention includes compounds that are useful in preventing or treating viral infections, such as viral infections caused by a filovirus, arenavirus, rhabdovirus, paramyxovirus, and/or retrovirus. The present invention further includes compositions comprising such compounds, and methods of treating a viral infection in a subject using such compounds.

  本发明包括一些有用的化合物，可用于预防或治疗病毒感染，如由丝状病毒、汉坦病毒、狂犬病毒、副粘病毒和/或逆转录病毒引起的病毒感染。本发明还包括包含这些化合物的组合物，以及使用这些化合物治疗受试者病毒感染的方法。
• Antiviral compounds and methods using same
  申请人：THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

  公开号：US10160756B2

  公开（公告）日：2018-12-25

  The present invention includes compounds that are useful in preventing or treating viral infections, such as viral infections caused by a filovirus, arenavirus, rhabdovirus, paramyxovirus, and/or retrovirus. The present invention further includes compositions comprising such compounds, and methods of treating a viral infection in a subject using such compounds.

  本发明包括可用于预防或治疗病毒感染的化合物，例如由丝状病毒、腺病毒、横纹肌病毒、副粘病毒和/或逆转录病毒引起的病毒感染。本发明还包括包含此类化合物的组合物，以及使用此类化合物治疗受试者病毒感染的方法。
• NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME
  申请人：The Trustees of The University of Pennsylvania

  公开号：EP3126005A1

  公开（公告）日：2017-02-08
• Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress
  作者：H. Marie Loughran、Ziying Han、Jay E. Wrobel、Sarah E. Decker、Gordon Ruthel、Bruce D. Freedman、Ronald N. Harty、Allen B. Reitz

  DOI：10.1016/j.bmcl.2016.06.053

  日期：2016.8

  We prepared a series of quinoxalin-2-mercapto-acetyl-urea analogs and evaluated them for their ability to inhibit viral egress in our Marburg and Ebola VP40 VLP budding assays in HEK293T cells. We also evaluated selected compounds in our bimolecular complementation assay (BiMC) to detect and visualize a Marburg mVP40-Nedd4 interaction in live mammalian cells. Antiviral activity was assessed for selected compounds using a live recombinant vesicular stomatitis virus (VSV) (M40 virus) that expresses the EBOV VP40 PPxY L-domain. Finally selected compounds were evaluated in several ADME assays to have an early assessment of their drug properties. Our compounds had low nM potency in these assays (e.g., compounds 21, 24, 26, 39), and had good human liver microsome stability, as well as little or no inhibition of P450 3A4. (C) 2016 Elsevier Ltd. All rights reserved.